New data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoActemra (known as Actemra outside Europe) is highly effective in improving the signs and symptoms of systemic juvenile idiopathic arthritis (SJIA), a severe childhood arthritis, where there are no currently licensed treatments.
ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well.
It works differently from all other medicines to fight RA, by specifically blocking the action of IL-6.
ACTEMRA is given by intravenous (IV) infusion about every four weeks. The infusion takes approximately one hour.